Want to see SNOA full AI Analyst Report?
Top Page
Sonoma Pharmaceuticals
(NASDAQ:SNOA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▲(31.58% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily held back by weak financial performance—ongoing operating losses and negative (and recently worsening) free cash flow despite revenue growth and stable gross margins. Technicals are modestly improved in the short term (above 20/50-day with positive MACD) but remain weak longer term (below 100/200-day). Valuation is constrained by a negative P/E and no dividend support, and a recent negative corporate event adds incremental risk.
Positive Factors
Revenue growth and stable gross margin
Revenue expansion alongside a steady gross margin indicates continued product demand and reasonably durable unit economics. If maintained, this growth can improve operating leverage as the company scales its commercialization base.
Negative Factors
Persistent operating and net losses
The company has not yet covered its operating cost base, so revenue growth has not translated into profitability. Continued losses could constrain reinvestment, weaken equity value over time and increase reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and stable gross margin
Revenue expansion alongside a steady gross margin indicates continued product demand and reasonably durable unit economics. If maintained, this growth can improve operating leverage as the company scales its commercialization base.
Read all positive factors
Sonoma Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks revenue into business lines or product groups (for example, prescription products, over‑the‑counter brands, and contract manufacturing). Highlights which segments drive sales and margins, and uncovers concentration risk if a single product or customer dominates. Growing revenue from diversified or recurring segments suggests more stable cash flow and a clearer path to valuation upside.
Breaks revenue into business lines or product groups (for example, prescription products, over‑the‑counter brands, and contract manufacturing). Highlights which segments drive sales and margins, and uncovers concentration risk if a single product or customer dominates. Growing revenue from diversified or recurring segments suggests more stable cash flow and a clearer path to valuation upside.
Data provided by:
The Fly
The FlySonoma Pharmaceuticals (SNOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.61M
Dividend YieldN/A
Average Volume (3M)65.28K
Price to Earnings (P/E)―
Beta (1Y)1.95
Revenue Growth47.00%
EPS Growth50.49%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.22
Shares Outstanding4,788,425
10 Day Avg. Volume126,678
30 Day Avg. Volume65,281
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.16
Price to Sales (P/S)0.18
P/FCF Ratio-0.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$23.91M
Sonoma Pharmaceuticals Business Overview & Revenue Model
Company Description
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hyg...
How the Company Makes Money
Sonoma Pharmaceuticals makes money primarily by selling Microcyn-based products and related formulations for wound care, dermatology, and antimicrobial/cleansing uses. Revenue is generated through (1) product sales in markets where the company sel...
Sonoma Pharmaceuticals Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.92M | 19.53M | 14.29M | 12.73M | 13.27M | 12.63M |
| Gross Profit | 8.53M | 7.42M | 5.46M | 4.75M | 4.48M | 3.99M |
| EBITDA | -1.59M | -2.32M | -2.77M | -4.86M | -5.06M | -5.22M |
| Net Income | -2.26M | -3.17M | -3.46M | -4.83M | -5.15M | -5.09M |
Balance Sheet | ||||||
| Total Assets | 18.11M | 13.96M | 13.69M | 14.74M | 16.23M | 18.84M |
| Cash, Cash Equivalents and Short-Term Investments | 5.34M | 2.40M | 5.37M | 3.13M | 3.82M | 7.40M |
| Total Debt | 739.00K | 842.00K | 305.00K | 608.00K | 849.00K | 1.37M |
| Total Liabilities | 11.51M | 10.87M | 9.28M | 8.60M | 8.25M | 10.15M |
| Stockholders Equity | 6.59M | 3.10M | 4.41M | 6.14M | 7.98M | 8.70M |
Cash Flow | ||||||
| Free Cash Flow | -2.15M | -4.13M | -168.00K | -2.42M | -6.42M | -4.38M |
| Operating Cash Flow | -2.03M | -3.93M | -88.00K | -2.40M | -6.15M | -4.25M |
| Investing Cash Flow | -125.00K | -192.00K | -80.00K | -2.00K | -258.00K | -99.00K |
| Financing Cash Flow | 4.29M | 477.00K | 3.03M | 1.68M | 2.49M | 7.40M |
Sonoma Pharmaceuticals Technical Analysis
Positive
1.14
Price Trends
1.23
Positive
1.33
Positive
2.23
Negative
Market Momentum
0.04
Negative
60.07
Neutral
64.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNOA, the sentiment is Positive. The current price of 1.14 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.23, and below the 200-day MA of 2.23, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.07 is Neutral, neither overbought nor oversold. The STOCH value of 64.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNOA.
Sonoma Pharmaceuticals Risk Analysis
Sonoma Pharmaceuticals disclosed 34 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sonoma Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $5.75B | 36.20 | -326.75% | ― | 9.28% | 4917.17% | |
54 Neutral | $2.05B | -1.15 | -55.97% | 11.50% | -4.18% | -2138.82% | |
53 Neutral | $676.51M | -7.94 | 243.68% | ― | 22.56% | 5.86% | |
53 Neutral | $212.95M | -33.33 | -20.23% | ― | 20.89% | 40.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $225.18M | -2.12 | -24.23% | ― | 6.50% | -613.22% | |
45 Neutral | $6.61M | -1.09 | -88.38% | ― | 47.00% | 50.49% |
* Healthcare Sector Average
SNOA
Sonoma Pharmaceuticals
1.33
-3.23
-70.83%
PRGO
Perrigo Company
14.37
-7.52
-34.35%
ORGO
Organogenesis Holdings
1.74
-3.38
-66.02%
AMRX
Amneal Pharmaceuticals
18.01
8.46
88.59%
AQST
Aquestive Therapeutics
5.16
1.33
34.73%
DERM
Journey Medical Corp
7.53
0.26
3.58%
Sonoma Pharmaceuticals Corporate Events
Business Operations and StrategyShareholder Meetings
Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting
Negative
Aug 19, 2026
On August 19, 2026, Sonoma Pharmaceuticals, Inc. convened an adjourned special meeting of stockholders that had been called pursuant to a proxy process initiated in early May 2026. The meeting covered 3,473,554 eligible common shares, but a quorum...
Private Placements and FinancingRegulatory Filings and Compliance
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity
Neutral
Jun 18, 2026
On September 26, 2025, Sonoma Pharmaceuticals, Inc. entered into an at-the-market issuance sales agreement with Ladenburg Thalmann Co. to sell shares of its common stock under an existing shelf registration, and between that date and the current ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.